Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy (ARCHER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04656561
Recruitment Status : Recruiting
First Posted : December 7, 2020
Last Update Posted : March 5, 2021
Sponsor:
Information provided by (Responsible Party):
Annexon, Inc.

Brief Summary:
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.

Condition or disease Intervention/treatment Phase
Geographic Atrophy Drug: ANX007 Other: Sham comparator Phase 2

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) - The ARCHER Study
Actual Study Start Date : February 26, 2021
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ANX007 Group 1
ANX007 administered every month
Drug: ANX007
Form: solution for injection; Route of Administration: IVT

Experimental: ANX007 Group 2
ANX007 administered every other month
Drug: ANX007
Form: solution for injection; Route of Administration: IVT

Sham Comparator: Sham Group 3
Sham injection administered every month
Other: Sham comparator
Form and Route of Administration: pressure to mimic IVT injection

Sham Comparator: Sham Group 4
Sham injection administered every other month
Other: Sham comparator
Form and Route of Administration: pressure to mimic IVT injection




Primary Outcome Measures :
  1. GA lesion growth rate [ Time Frame: Baseline to Month 12 ]
    Change in GA lesion area as assessed by fundus autofluorescence (FAF)


Secondary Outcome Measures :
  1. Safety: Participants with treatment-emergent adverse events (TEAEs) [ Time Frame: Baseline to Month 18 ]
    Number of participants with TEAEs

  2. Best corrected visual acuity (BCVA) [ Time Frame: Baseline to Month 18 ]
    Change from baseline in BCVA as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) test chart

  3. Low-luminance BCVA (LL-BCVA) [ Time Frame: Baseline to Month 18 ]
    Change from baseline in LL-BCVA

  4. Low-luminance visual acuity deficit (LL-VD) [ Time Frame: Baseline to Month 18 ]
    Change from baseline in LL-VD



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of geographic atrophy of the macula secondary to age-related macular degeneration as determined by the Investigator and confirmed by the Central Reading Center.
  • GA lesion must have the following characteristics as determined by the independent Central Reading Center based on assessment of FAF imaging at screening:

    1. Well-demarcated GA with a total area (baseline lesion size) ≥2.5 mm2 and ≤17.5 mm2.
    2. If GA is multifocal, at least 1 focal lesion must measure ≥1.25 mm2 with the overall aggregate area of GA as specified above.
    3. Presence of hyper autofluorescence, any pattern, in the junctional zone of the GA. Absence of hyper autofluorescence (ie, pattern = none) is exclusionary.
    4. The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any peripapillary atrophy.
  • Normal luminance best corrected visual acuity (BCVA) of 24 to 83 letters, inclusive, using Early Treatment Diabetic Retinopathy Study (ETDRS) charts (20/25 to 20/320 Snellen equivalent, inclusive).
  • A female patient is eligible if she is not pregnant or breastfeeding and is a woman of non-childbearing potential or is using a contraceptive method that is highly effective, with a failure rate of <1% during the study intervention period and for at least 30 days after the last dose of study intervention.

Exclusion Criteria:

  • Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (eg, plaquenil maculopathy) in either eye.
  • Any evidence of choroidal neovascularization (CNV) in the study eye:

    1. Any history of CNV of any cause based on medical history.
    2. Evidence of prior or active CNV or related findings (eg, retinal pigment epithelial rips or tears) based on FAF, SD-OCT imaging, intravenous fluorescein angiography (IVFA) and color fundus photo as assessed by the Central Reading Center.
  • Spherical equivalent of -8.00 diopters (D) myopia or higher in the study eye.
  • Uncontrolled glaucoma in the study eye (IOP >25 mmHg despite treatment with anti- glaucoma medication) or history of neovascular glaucoma.
  • History of glaucoma filtration surgery, minimally-invasive glaucoma surgery involving an implant, or vitrectomy surgery, or other procedure in the study eye that could affect drug distribution and/or clearance.
  • Any current or prior ocular disease, other than geographic atrophy, that in the opinion of the Investigator could interfere with the conduct of the study including, but not limited to, insufficient pupil dilation, retinal or optic nerve disease, media opacity, or aphakia in the study eye.
  • History of any prior IVT treatment for any indication in the study eye.
  • Any prior treatment for AMD in the study eye (eg, surgical, radiation, thermotherapeutic, or laser intervention), except oral supplements or minerals.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04656561


Contacts
Layout table for location contacts
Contact: Study Coordinator 650-822-5500 clinicaltrials@annexonbio.com

Locations
Layout table for location information
United States, Arizona
Site 5 Recruiting
Phoenix, Arizona, United States, 85053
Contact: Study Coordinator    650-822-5500    clinicaltrials@annexonbio.com   
United States, California
Site 2 Recruiting
Beverly Hills, California, United States, 90211
Contact: Study Coordinator    650-822-5500    clinicaltrials@annexonbio.com   
United States, Florida
Site 6 Recruiting
Winter Haven, Florida, United States, 33880
Contact: Study Coordinator    650-822-5500    clinicaltrials@annexonbio.com   
United States, Maryland
Site 1 Recruiting
Hagerstown, Maryland, United States, 21502
Contact: Study Coordinator    650-822-5500    clinicaltrials@annexonbio.com   
United States, Massachusetts
Site 3 Recruiting
Springfield, Massachusetts, United States, 01107
Contact: Study Coordinator    650-822-5500    clinicaltrials@annexonbio.com   
United States, Texas
Site 4 Recruiting
Austin, Texas, United States, 78750
Contact: Study Coordinator    650-822-5500    clinicaltrials@annexonbio.com   
Sponsors and Collaborators
Annexon, Inc.
Investigators
Layout table for investigator information
Study Director: Clinical Trials Annexon, Inc.
Layout table for additonal information
Responsible Party: Annexon, Inc.
ClinicalTrials.gov Identifier: NCT04656561    
Other Study ID Numbers: ANX007-GA-01
First Posted: December 7, 2020    Key Record Dates
Last Update Posted: March 5, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Geographic Atrophy
Atrophy
Pathological Conditions, Anatomical
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases